Biotech startups that raised Series C in San Francisco, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Chai Discovery | San Francisco | Series C | $400.0M | 2026-07-14 |
| Terremoto Biosciences | San Francisco | Series C | $108.0M | 2026-04-15 |
| Loyal | San Francisco | Series C | $100.0M | 2026-02-11 |
| Culture Biosciences | San Francisco | Series C | $80.0M | 2025-12-16 |
| Frontier Medicines | San Francisco | Series C | $20.0M | 2024-06-25 |
| Asher Bio | San Francisco | Series C | $55.0M | 2024-04-16 |
| Unlearn.AI | San Francisco | Series C | $50.0M | 2024-02-08 |
| Aizon | San Francisco | Series C | $20.0M | 2024-02-07 |
8 rows of the CSV in 5 of its 18 columns.
- The 26 biotech startups in San Francisco, United States whose last round is Series C have raised $3.7B in total.
- 6 of them closed their most recent round in the last 12 months, $897.0M combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Trellis Bioscience's $9.0M Series C on 16 July 2026.
- Y Combinator is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 23 companies (88%).
- 12% were founded in 2020 or later; the median founding year is 2013.
- The most common team size is 11 to 50 employees (42% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
6 of 26| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
| Unlearn.AI | Unlearn.AI uses AI, digital twins, and statistical methods to enable smaller, more efficient clinical trials. | Artificial intelligence | Series C | $50.0M | 2024-02-08 | $134.8M | Alumni Ventures, Insight Partners, 8VC +2 | 51 to 100 | 2017 |
| Aizon | Aizon provides a cloud-based SaaS platform that improves industrial processes in biotech and pharma. | Artificial intelligence | Series C | $20.0M | 2024-02-07 | $44.8M | 500 Global, FundersClub, Uncork Capital +2 | 101 to 250 | 2013 |
Table 1. Biotech startups that raised Series C in San Francisco, United States: the 6 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 26.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 3 | Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| 4 | Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
Table 2. Biotech startups that raised Series C in San Francisco, United States: the 4 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 5 | 19% | 1 | Culture Biosciences |
| 2 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 3 | 12% | 1 | Loyal |
| 3 | Alumni Ventures | Angel group | Manchester, United States | 3 | 12% | ||
| 4 | RA Capital Management | Startup incubator | Boston, United States | 2 | 8% | ||
| 5 | Felicis | Venture capital firm | Menlo Park, United States | 2 | 8% | ||
| 6 | OpenAI | San Francisco, United States | 1 | 4% | 1 | Chai Discovery | |
| 7 | Thrive Capital | Startup incubator | New York, United States | 1 | 4% | 1 | Chai Discovery |
| 8 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 1 | 4% | 1 | Terremoto Biosciences |
| 9 | Third Rock Ventures | Venture capital firm | Boston, United States | 1 | 4% | 1 | Terremoto Biosciences |
| 10 | EcoR1 Capital | Private equity firm | San Francisco, United States | 1 | 4% | 1 | Terremoto Biosciences |
| 11 | Cormorant Capital | Venture capital firm | New York, United States | 1 | 4% | 1 | Terremoto Biosciences |
| 12 | OrbiMed | Private equity firm | New York, United States | 1 | 4% | 1 | Terremoto Biosciences |
| 13 | First Round Capital | Venture capital firm | Philadelphia, United States | 1 | 4% | 1 | Loyal |
| 14 | Collaborative Fund | Venture capital firm | New York, United States | 1 | 4% | 1 | Loyal |
| 15 | Quiet Capital | Venture capital firm | San Francisco, United States | 1 | 4% | 1 | Loyal |
Table 3. Biotech startups that raised Series C in San Francisco, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 23 | 88% | $3.2B |
| Software | 8 | 31% | $1.5B |
| Artificial intelligence | 4 | 15% | $944.7M |
| Hardware | 4 | 15% | $668.5M |
| Fintech | 2 | 8% | $140.0M |
Table 4. Biotech startups that raised Series C in San Francisco, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 26 | 100% | $55.0M |
Table 5. Biotech startups that raised Series C in San Francisco, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| July 2026 | 2 | 33% | $409.0M |
| April 2026 | 1 | 17% | $108.0M |
| February 2026 | 1 | 17% | $100.0M |
| January 2026 | 1 | 17% | $200.0M |
| December 2025 | 1 | 17% | $80.0M |
Table 6. Biotech startups that raised Series C in San Francisco, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 5 | 19% | $817.0M |
| 2025 | 2 | 8% | $263.0M |
| 2024 | 6 | 23% | $145.0M |
| 2022 | 1 | 4% | $60.0M |
| 2021 | 1 | 4% | $220.0M |
| 2020 | 1 | 4% | $145.6M |
Table 7. Biotech startups that raised Series C in San Francisco, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 4% |
| 2020 to 2022 | 2 | 8% |
| 2015 to 2019 | 8 | 31% |
| 2010 to 2014 | 8 | 31% |
| Before 2010 | 7 | 27% |
Table 8. Biotech startups that raised Series C in San Francisco, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 11 to 50 | 11 | 42% |
| 51 to 100 | 8 | 31% |
| 101 to 250 | 6 | 23% |
| 10,001 or more | 1 | 4% |
Table 9. Biotech startups that raised Series C in San Francisco, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C and its headquarters is in San Francisco, United States. On 16 November 2026 that is 26 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 6 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 26 rows: 2 have no round amount, 0 no city and 2 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in San Francisco, United States whose last round is Series C are on the list?
- 26, in the file dated 16 November 2026. 6 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 26 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.